Navigation Links
ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
Date:1/18/2008

LEUVEN, Belgium and LUND, Sweden, January 18 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International AB (Nordic Exchange: BINV) announce today that they have received approval from the regulatory authorities in Denmark to initiate a Phase I clinical trial of the novel anti-cancer agent TB-403. TB-403 is a monoclonal antibody that targets the angiogenic factor PlGF (placental growth factor). TB-403 has demonstrated strong inhibition of PlGF-associated angiogenesis and tumour growth in animal models, without affecting healthy tissues. This product candidate is being developed within the framework of the alliance between ThromboGenics and BioInvent.

The first Phase I clinical study will be performed in Denmark, with the first subject expected to be recruited in the study soon. The trial is a double-blind and within-group randomised trial testing single-doses of TB-403 or placebo at three escalating levels in 16 healthy male subjects. The objective is to monitor tolerability and safety after three single escalating intravenous doses. Furthermore, pharmacokinetics will be determined with the objective to create the basis for a safe and efficient introduction of the compound in the subsequent repeat-dose trial.

The repeat-dose trial is expected to start during the third quarter 2008. The trial will be a study of tolerability, pharmacokinetics and pharmacodynamics in patients with advanced cancer. Cohorts of patients having failed prior therapy will be given escalating doses.

Prof. Desire Collen, CEO and Chairman of ThromboGenics, commenting on today's announcement, said: "I am very pleased with the progress made with TB-403. Seeing this novel monoclonal antibody enter the clinic is an important milestone for us and our partner BioInvent. Preclinical data has shown that TB-403 has a unique mode action, blocking the formation of new blood vessels in the cancer tumour without affecting
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
2. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
3. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
4. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
5. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
6. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
7. Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System
8. Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer
9. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
10. Genta Receives Notice of Non-Compliance With NASDAQ Rule
11. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... (PRWEB) September 16, 2014 Convoy ... safe and effective products to treat patients directly ... of a proprietary SPACEā„¢ Technology Platform announced today ... President will present at the White Hat Life ... the Hyatt Regency Phoenix. In addition, interested ...
(Date:9/16/2014)... , September 16, 2014 BCC ... MARKET FOR STEM CELLS , the global market for ... billion by 2018, with a five-year compound annual growth ... witnessed in the Americas with growth projections of $2.2 ...      (Logo: http://photos.prnewswire.com/prnh/20140805/700528) , Unlike other ...
(Date:9/15/2014)... Cancer Immunotherapy Market : Immune ... is a new market research report announced by ... types of therapeutics that have become the major ... (which is often called "immuno-oncology") in recent years: ... immunotherapy. , The regular use of immunotherapy ...
(Date:9/15/2014)... very idea of fibers made of carbon nanotubes is neat, ... , The single-walled carbon nanotubes in new fibers created at ... a process designed by chemist Angel Mart and his colleagues. ... its results this month in the journal ACS Nano ... drawn together into a fiber. , Left to their own ...
Breaking Biology Technology:Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 2Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 3Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 2Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5Rice rolls 'neat' nanotube fibers 2Rice rolls 'neat' nanotube fibers 3
... Md., May 13 /Xinhua-PRNewswire/ -- Chindex International,Inc. (Nasdaq: ... services and products in the People,s Republic of China,announced ... the,Securities and Exchange Commission (SEC) that, if declared effective ... time to time, up to $100 million,of its common ...
... May 13 Interleukin Genetics,Inc. (Amex: ILI ) ... present at the Rodman and Renshaw 5th Annual Global,Healthcare ... CEST (4:00 a.m.,EDT). The conference will be held at ... live audio webcast of the presentation will be available ...
... International,Inc. (Nasdaq: CHDX ) a leading independent American ... Republic of China,announced that it intends to release its ... on Thursday, June 12, 2008., Chindex,s management will ... at 9:00 a.m. Eastern Time to discuss its financial ...
Cached Biology Technology:Chindex International Announces Shelf Registration, Related Strategy and Guidance 2Chindex International Announces Shelf Registration, Related Strategy and Guidance 3Chindex International Announces Shelf Registration, Related Strategy and Guidance 4Chindex International Announces Shelf Registration, Related Strategy and Guidance 5Interleukin Genetics to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference 2Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Fourth Quarter and Year End Results on Thursday, June 12, 2008 2Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Fourth Quarter and Year End Results on Thursday, June 12, 2008 3
(Date:9/16/2014)... to make ethical choices such as buying clothing not ... fair-trade coffee, and bringing their own bags when they ... Journal of Consumer Research , ethical consumption is ... emotions about unethical practices into action. , "Advocates of ... and human costs of the products they choose, but ...
(Date:9/16/2014)... , Sept. 16, 2014  Cross Match Technologies, ... solutions, announced today the launch of its Verifier ... the identity of an individual using their secure ... Sentry rapidly reads credential documents with embedded biometric ... matching the biometric to a live scan of ...
(Date:9/15/2014)... so-called central dogma of molecular biologythat DNA makes ... explanation for how genetic information is deciphered and ... of course, the process is vastly more complicated ... ago by Nobel Laureate Francis Crick, co-discoverer of ... multiple types of RNA, three of whichmessenger RNA ...
Breaking Biology News(10 mins):Why are consumers willing to spend more money on ethical products? 2Cross Match Launches New Identity Management Handheld Solution 2Scientists discover RNA modifications in some unexpected places 2
... Since the observations made by English naturalist Charles Darwin ... how physical barriers, such as isolation on a particular ... through the process of natural selection. Natural selection ... become more common in successive generations, while unfavorable heritable ...
... of the world,s cities lie on a shoreline, and by ... coastal cities. From San Francisco to Boston to Hong Kong, ... that set up shop here eons ago. "We need ... and determine ways to solve problems for both," said Brian ...
... a dog-eat-dog world, and with the exception of the top ... reality, a tiny insect that eats plants has learned to ... predator. The pest is called the cycad aulacaspis ... has caused immeasurable loss of biodiversity. Cycads belong to an ...
Cached Biology News:LSU professor discovers how new corals species form in the ocean 2LSU professor discovers how new corals species form in the ocean 3Sustaining Coastal Cities Conference at Northeastern University 2Pest uses plant hairs for protection 2
... Kinase. This product is expected ... other mammalian species but has not ... a single precipitin line against partially ... shown to react with all forms ...
... Features Convenient platform for tube handling and ... x 0.2ml V-bottom tubes - 96 ... - Thermo-Fast® 96 Non-Skirted Plate ... - 48 x 0.5ml Thermo-Tubes Multiple workstations can ...
... detection systems provide linking and labelling ... species specific primary antibodies for visualising ... is accomplished using an ultra-sensitive indirect ... labelling technology. Secondary antibodies are polymerised ...
... from Thermus aquaticus expressed in E. coli; ... of 250 units enzyme/tube and Buffer I ... the same enzyme as AmpliTaq DNA Polymerase ... separation process to ensure that contaminating bacterial ...
Biology Products: